SGLT-2 Inhibitors Market is expected to hit US$ 32.16 billion by 2033 | Leading Companies - Boehringer Ingelheim International GmbH., Johnson & Johnson Services, Inc., AstraZeneca., Eli Lilly and Company.

Market Size and Growth:

The SGLT-2 Inhibitors Market size reached US$ 17.95 billion in 2024 and is expected to reach US$ 32.16 billion by 2033, growing at a CAGR of 7.1% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "SGLT-2 Inhibitors Market Size 2026". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/sglt-2-inhibitors-market?sz

The SGLT-2 Inhibitors Market refers to the global industry focused on the development, manufacturing, and commercialization of sodium-glucose cotransporter-2 (SGLT-2) inhibitor drugs used primarily to manage type 2 diabetes. These medications lower blood glucose by preventing glucose reabsorption in the kidneys, promoting its excretion through urine. The market includes branded and generic products, combination therapies, and expanding indications such as heart failure and chronic kidney disease, driven by rising diabetes prevalence and cardiovascular risk management demand.

Recent Key Developments of United States:

✅ January 2026: SGLT-2 inhibitors demonstrated good tolerability in sickle cell disease (SCD) nephropathy patients, opening potential new indications based on clinical tolerance data.

✅ December 2025: Global market analysis noted expanding SGLT-2 use beyond diabetes into cardiology and nephrology, boosting multi-specialty adoption and value-based care integration in the US.

✅ November 2025: A comprehensive research report highlighted rising demand for SGLT-2 inhibitors driven by their antidiabetic efficacy and cardiovascular benefits, signaling sustained market momentum.

Recent Key Developments of Japan:

✅ February 2026: Tanabe Pharma received additional approval for CANAGLU® OD Tablets (canagliflozin), marking the first orally disintegrating tablets for this SGLT-2 inhibitor to improve patient convenience.

✅ January 2026: Market forecasts emphasized Japan's rapid SGLT-2 growth due to aging population, diabetes prevalence, and strong adoption for cardiovascular/renal benefits amid personalized medicine push.

✅ December 2025: Sawai and T's Pharma secured generics for Forxiga (dapagliflozin) by navigating patent challenges, paving the way for increased generic competition in the SGLT-2 market.

List of the Key Players in the SGLT-2 Inhibitors Market:

Boehringer Ingelheim International GmbH.
Johnson & Johnson Services, Inc.
AstraZeneca.
Eli Lilly and Company.
Pfizer Inc.
Merck & Co., Inc.
TheracosBio, LLC
Lexicon Pharmaceuticals, Inc.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/sglt-2-inhibitors-market?sz

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Segments Covered in the SGLT-2 Inhibitors Market:

By Drug Type: Bexagliflozin, Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Sotagliflozin.

By Indication: Type-2 Diabetes, Chronic Kidney Disease (CKD), Heart Failure.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=sglt-2-inhibitors-market

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of SGLT-2 Inhibitors manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of SGLT-2 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the SGLT-2 Inhibitors Market in 2026?
◆ What is the projected growth rate of the SGLT-2 Inhibitors Market through 2034?
◆ Who are the key players in the SGLT-2 Inhibitors Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.